NeuroSense Therapeutics Locks Database For Phase 2 RoAD Study Of PrimeC In Alzheimer's; Topline Results Expected Q1 2026

NeuroSense Therapeutics Ltd. ("NeuroSense") today announced that the database has been locked for its proof-of-concept, Phase 2 clinical trial of PrimeC in Alzheimer's disease (AD), known as the RoAD study. This key milestone paves the way for final statistical analyses, with topline results expected in the first quarter of 2026.

Database lock confirms that all clinical data for the RoAD study have been collected, cleaned, and finalized for analysis, marking the formal conclusion of trial data collection. Based on the data accumulated from the eight enrolled patients, including a broad and diverse set of biomarkers, NeuroSense determined that the trial had reached sufficient maturity to proceed to analysis without further extending enrollment.